Aug 6, 2021
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...
852
Dec 8, 2018
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...
320
Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...
356
Dec 14, 2017
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...
355
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
191
Dec 16, 2016
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...
96
Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
123
Dec 7, 2007
NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)
NCT00473590: Phase 2: A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma...
237